Cipher Pharmaceuticals Inc
Open
$17.65
Prev. Close
$17.58
High
$17.69
Low
$17.61
Market Snapshot
$359.11M
12.4
0.65
$50.05M
5
Cipher Pharmaceuticals, Inc. engages as a specialty pharmaceutical company, which have diversified portfolio of commercial and early to late-stage products. The company is headquartered in Mississauga, Ontario. The company went IPO on 2004-02-25. The firm acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. The company delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. The company also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.
emptyResult
Cipher Pharmaceuticals, Inc. engages as a specialty pharmaceutical company, which have diversified portfolio of commercial and early to late-stage products. The company is headquartered in Mississauga, Ontario. The company went IPO on 2004-02-25. The firm acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. The company delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. The company also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.
Recently from Cashu
Cipher Pharmaceuticals Secures Shareholder Support for Governance and Strategic Initiatives
Cipher Pharmaceuticals Strengthens Governance and Strategic Direction Through Shareholder Approval Cipher Pharmaceuticals Inc. successfully concludes its annual and special meeting of shareholders on…
Cipher Pharmaceuticals Inc. Launches Share Buyback Program to Enhance Shareholder Value
Cipher Pharmaceuticals Initiates Normal Course Issuer Bid to Optimize Shareholder Value Cipher Pharmaceuticals Inc. (TSX: CPH) announces the commencement of a normal course issuer bid (NCIB), having r…
Cipher Pharmaceuticals Inc. Launches Share Buyback Plan to Boost Shareholder Value
Cipher Pharmaceuticals Initiates Share Buyback Plan to Enhance Shareholder Value Cipher Pharmaceuticals Inc. announces its intention to launch a normal course issuer bid (NCIB) for its common shares,…